Fair value (multi-method)
Four independent methods triangulate what EW is worth. The headline is the Forward-DCF intrinsic value at a normalized growth rate; the margin of safety compares it to the current price.
Estimated fair value (Forward DCF)
$42.27
Method range
$16.24 – $99.40
median $66.73
Valuation methods
Each method’s implied fair value per share and its upside versus the current price. Missing methods (no analyst coverage, negative earnings, etc.) are shown as “—”.
| Method | Fair value | Upside vs price |
|---|---|---|
| Forward DCF | $42.27 | -49.90% |
| Exit multiple | $91.18 | +8.08% |
| Analyst target | $99.40 | +17.81% |
| Graham number | $16.24 | -80.75% |
- Forward DCF$42.27
- Exit multiple$91.18
- Analyst target$99.40
- Graham number$16.24
Stock price
$84.37
EPS (TTM)
$1.88
5Y EPS CAGR
7.1%
Fair value @ hist. growth
$42.27
This analysis is for informational purposes only and is not financial advice. Scenario prices and DCF-style figures depend on your assumptions and data from public filings and estimates. They are not forecasts of future returns.
Implied EPS growth
16.2%
per year over your projection horizon
Margin of safety -99.6% vs hist-growth DCF
Historical 5Y CAGR
7.1%
Your model implies
16.2%
Next-year analyst consensus
60.1%
Model inputs
Move sliders to test how the reverse DCF reacts. Historical-growth markers show where the company has actually grown over the last cycle.
Sensitivity — implied growth vs your assumptions
Each cell shows the per-share growth rate the market would need to justify the current price at that combination of discount rate (rows) and terminal growth (columns). Your selected inputs are highlighted.
| Row axis: discount rate. Column axis: terminal growth.Terminal g →↓ Discount | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 6.9% | 12.7% | 11.8% | 10.7% | 9.6% | 8.3% |
| 7.9% | 15.2% | 14.5% | 13.6% | 12.7% | 11.7% |
| 8.9% | 17.6% | 16.9% | 16.2% | 15.4% | 14.6% |
| 9.9% | 19.8% | 19.2% | 18.6% | 17.9% | 17.2% |
| 10.9% | 21.9% | 21.4% | 20.8% | 20.2% | 19.6% |
Historical multiples
Each bar is the trailing five-year range (low left, high right). Filled portion runs from low to today; the dot marks today; the small tick marks the five-year median. Low, median, and high are listed under each bar.
PEG
0.10
Low vs growth
Net cash
$2.23B
Total debt − cash
Beta
0.86
Vs market benchmark
Annual diluted EPS
Per-share earnings by fiscal year — last 5 years anchor the CAGR reference above.
Frequently asked questions
Edwards Lifesciences (EW) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.